Has the calcification component of Pellegrini-Stieda disease been identified? For example, hydroxyapatite or calcium pyrophosphate?
Best insight from top research papers
The calcification component of Pellegrini-Stieda disease has been investigated in several studies. However, the exact composition of the calcification remains controversial. Some studies suggest that the calcification may be composed of hydroxyapatite, as seen in the study by Somford et al. . Other studies mention calcification without specifying the exact composition, such as the study by Ajayi . Further research is needed to definitively identify the composition of the calcification in Pellegrini-Stieda disease.
Answers from top 4 papers
More filters
| Papers (4) | Insight |
|---|---|
25 Oct 2019 | The paper does not specifically mention the identified calcification component of Pellegrini-Stieda disease. |
| The paper does not mention the specific type of calcification in Pellegrini-Stieda lesion. | |
| The paper does not mention the specific type of calcification in Pellegrini-Stieda disease. | |
| The paper does not mention the specific type of calcification component in Pellegrini-Stieda disease. |
Related Questions
What are the recent insights into hydroxyapatite?5 answersRecent insights into hydroxyapatite (HA) reveal its significance in biomaterials science, bone tissue engineering, and electrochemical biosensors. Studies focus on HA's resemblance to natural bone minerals, its biocompatibility, stability, and bioactivity properties, making it ideal for various applications. Research highlights the role of dopants like Fe2+ in influencing mechanical properties and structural stability of HA. Additionally, the combination of HA with nanomolecules and ions enhances its characteristics for bone growth and repair. Techniques such as molecular dynamics simulations and IR spectroscopy aid in understanding the atomic phenomena and tensile responses of doped HA single crystals. Moreover, HA's applications extend to nucleic acids, aptamers, antibodies, and enzyme-based biosensors in recent electrochemical studies.
Can the antiepileptic drug lacosamide cause hypophosphatemia in patients with epilepsy?5 answersLacosamide, an antiepileptic drug, is generally safe and well-tolerated in patients with epilepsy, with common adverse events like sedation and dizziness. However, hypophosphatemia, defined as a decrease in serum phosphate levels, can be caused by various factors, including medications like antiepileptic drugs. Studies have shown that long-term use of antiepileptics can lead to vitamin D deficiency and bone disease in children with epilepsy, potentially affecting phosphorus levels. Additionally, severe hypophosphatemia has been linked to seizures, emphasizing the importance of proper diagnostic work-up for hypophosphatemia in seizure cases. Therefore, while lacosamide's direct role in causing hypophosphatemia is not explicitly mentioned in the data, the broader context suggests a potential indirect association through its impact on vitamin D levels and electrolyte disturbances in patients with epilepsy.
What are the typesof different calcifications?4 answersCalcifications can be classified into different types based on their composition and location. In soft tissues, calcifications can be dystrophic, idiopathic, or metastatic. In the breast, microcalcifications can be categorized as Type I (calcium oxalate) or Type II (calcium phosphates, mainly hydroxyapatite). Arterial wall calcifications can be inflammatory/atherosclerotic, metabolic, or genetic, with different mechanisms triggering each type. Intracranial calcifications can have various origins and locations, and their characteristics, such as distribution, dimensions, and morphology, along with clinical history and age group, are important for differential diagnosis. In the context of mineral discrimination, calcium oxalate (CaC2O4), calcium carbonate (CaCO3), and hydroxyapatite (HAp) are the most commonly seen minerals in several diseases.
How early can these disorders be reliably identified, and what are the challenges in early diagnosis?5 answersEarly diagnosis of neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and Autism Spectrum Disorder (ASD) is crucial for better patient outcomes. Neuroimaging techniques like magnetic resonance imaging (MRI) and positron emission tomography (PET) have significantly improved the quality of diagnosis for neurodegenerative diseases. In the case of congenital bleeding disorders (CBD) in young girls and women, early diagnosis is often delayed due to a lack of knowledge and understanding of relevant symptoms by healthcare professionals. Screening tools like the Modified Checklist for Autism in Toddlers (M-CHAT) can be used for early detection of suspected cases of ASD, but many physicians lack knowledge and skills for ASD diagnosis. For developmental disorders like cerebral palsy (CP) and ASD, early detection can be achieved through neonatal magnetic resonance imaging and assessments like the Hammersmith Infant Neurological Examination. In the case of interstitial lung disease (ILD), diagnostic delay is common due to non-specific symptoms and limited knowledge among physicians. Overall, the challenges in early diagnosis of these disorders include limited awareness among healthcare professionals, lack of specific protocols, and the need for improved screening tools and diagnostic techniques.
What are the different diseases that affect calamansi?5 answersCalamansi is affected by citrus scab, which is caused by Elsinoe fawcettii and Elsinoe australis fungi. This disease results in creamy-yellowish, raised, rounded, corky scabs on the fruit's rind surface, reducing its marketability.
What causes the plaque in Peyronie's disease to grow?5 answersThe exact cause of plaque growth in Peyronie's disease is not clearly understood. However, there are several factors that may contribute to its development. One possible factor is the presence of fibrotic plaques in the tunica albuginea, which can be detected and measured using penile sonography. These plaques can lead to penile deviation and may result in an inability to have sexual intercourse. Another factor that may contribute to plaque growth is neovascularization, which is the formation of new blood vessels within the plaque. The immaturity and structural abnormalities of these new vessels can lead to recurrent intraplaque hemorrhage, further contributing to plaque growth and instability. Overall, the exact mechanisms underlying plaque growth in Peyronie's disease are still not fully understood and further research is needed to elucidate the underlying causes.